Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI chatbot could calm nerves before prostate surgery

NCT ID NCT07082049

Symptom relief Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This trial tests whether an AI-powered chatbot can help reduce anxiety and improve coping in men about to have prostate cancer surgery. Participants will either receive standard preoperative communication or also have access to a large language model (LLM) that answers their questions about diagnosis, treatment, and risks. Researchers will measure changes in anxiety, emotional state, and heart rate, as well as how much time the chatbot saves clinicians.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LLM-assisted communication (AI chatbot)
What this could lead to
If it works, this could offer a simple, scalable way to ease anxiety and save clinician time before prostate cancer surgery.
What could go wrong
This is a small, early-stage trial. The AI responses are reviewed by researchers, so real-world use may differ. Benefits may not be large or lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Newly diagnosed prostate adenocarcinoma confirmed by histopathology; 2. Age 18 years or older; 3. Must be a candidate for radical prostatectomy, including but not limited to laparoscopic radical prostatectomy (LapRP) and robot-assisted radical prostatectomy (RARP); 4. Ability to independently complete questionnaire filling and possess basic language comprehension ability; 5. Ability to understand and willingness to sign informed consent. Exclusion Criteria: 1. A history of severe diagnosed mental illness (such as depression, anxiety disorder, insomnia); 2. A history of diagnosed cognitive dysfunction (such as intellectual disability, Parkinson's disease); 3. Requires emergency surgery (within 72 hours after diagnosis); 4. Has participated in other interventional clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder prostate adenocarcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.